CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Earns Coverage for DehydraTECH(TM)’s Potential Market Reach, Multiple Uses

Lexaria Bioscience Corp. (NASDAQ: LEXX) was recently part of coverage by Zacks Small-Cap Research analysts based on its market potential. Zacks, which focuses its coverage on small and micro-cap companies it regards as under-followed or under-valued by the broader market in an effort to benefit investors as well as worthy innovators, valued the company at $15 per share. The valuation was based on the company’s portfolio supporting Lexaria’s patented DehydraTECH(TM) consumption and the multiple potential uses of the technology. The technology is also relatively low-cost, with the capacity to produce up to 400,000 consumer packaged goods through existing manufacturer relationships. A recent article reads, “Zacks notes the potential market reach of Lexaria’s technology if regulatory approved for use in pharmaceuticals, given that hypertension affects about 150 million people nationwide and over a billion worldwide, many of whom find existing medicines less than optimal. The ongoing COVID pandemic has also heightened attention on the need for antivirals to treat ever-present virus infections. And there are about a billion smokers worldwide who could potentially benefit from alternative methods of delivering nicotine to avoid the lung-deleterious effects of inhaling burned or vaporized substances.”

To view the full article, visit https://cnw.fm/c2KFS

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1-2 hours to minutes and mask unwanted tastes; it is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”) and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Sprout AI Inc. (CSE: SPRT) to Provide Cultivation Services for Company Offering Plant-Based Medical Products

Sprout AI(CSE: SPRT), a technologically focused, sustainable vertical farming company that has developed scalable, AI-controlled aeroponic cultivation habitats, will be providing cultivation services for JT Medical. JT Medical has announced that it is accepting memorandums of understanding (“MOUs”) from researchers looking to obtain high-quality, repeatable batch, plant-based medical products derived from regulated plants. The company noted that those plants may include cannabis, psilocybin mushroom and peyote. In the announcement, JT Medical said that SPRT provides self-contained habitats used in the process of producing its high-quality, repeatable batches. The habitats provide control of variables that impact crop duplication. JT Medical explained that the Sprout AI habitats will be operated via One System One Solution enterprise resource planning and compliance (“ERPc”) software. This process provides key information to researchers that enable them to track batches from seed, clone or tissue sample through to the final use or product. “Sprout AI habitats are used to ensure the replication of active medicinal plant ingredients as well as terpene, flavonoids and other desired components,” the company stated in the press release. “This enables both short-, mid- and long-term studies are derived from the ‘same’ product for medical research and efficacy reports.”

To view the full press release, visit https://cnw.fm/ynnQJ

About Sprout AI Inc.

Sprout AI is a vertical farming technology company in the business of planning, designing, manufacturing and/or assembling sustainable and scalable AI-controlled vertical cultivation equipment for indoor vertical farming. The adaptive technology produces an environment with improved growing parameters and early detection of adverse conditions, resulting in consistent and repeatable crops with shorter cultivation cycles, independent of geographic climates. The self-contained multilevel rolling rack technology increases the cubic cultivation area while mitigating the risk of outside and cross-contaminants. For more information about the company, visit www.SproutAI.solutions.

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Top IRS Official Reveals Cannabis Banking Reform Can Ease Tax Organization’s Work

Marijuana businesses have been unable to access financial services such as deposit accounts, cashless payments and loans since legal sales began in America. This is mostly due to the controversial plant’s classification as a Schedule I controlled drug, and it has had wide-ranging consequences on both cannabis businesses and federal authorities.

Players in the cannabis space are forced to transact on a cash-only basis, increasing their chances of robberies and making it difficult to account for and pay taxes. Furthermore, federal authorities, the IRS specifically, don’t often receive taxes that are due, and when they do, it is usually in large amounts of cash.

For quite a while, stakeholders, drug reform activists and lawmakers have urged federal authorities to allow cannabis businesses to access banking services. Recently, a top IRS official joined the growing number of figures that support banking services for America’s state-legal cannabis industry after she claimed that cannabis banking reform would ease the taxman’s work.

The IRS would like to get paid, IRS official Cassidy Collins said during an event hosted by UCLA’s Annual Tax Controversy Institute, and granting marijuana access to the banking system will be a big help. As it stands, marijuana presents a “special type of collection challenge” since the plant is federally outlawed and mostly stuck to cash-only payments that make it harder for the federal agency to receive taxes from cannabis businesses, Cassidy says.

She notes that the cash-only payment crisis can be attributed to two things: customers that are avoiding a paper trail that shows they purchased cannabis and banks that avoid working with cannabis businesses due to fear of reprisal by the federal government. Fortunately, lawmakers have introduced cannabis reform bills to give the industry access to banking services, and one of them has made headway.

Cassidy, a senior counsel in the IRS Office of Chief Counsel, says that while her views on cannabis banking may not represent the IRS’s or her own opinion, it would make the agency’s job of collecting taxes a lot easier. The Internal Revenue Service’s main objective, after all, is to collect taxes, and any legislation that eases the agency’s efforts is welcome.

Currently, cannabis business operators have to visit IRS tax assistance centers, which accept cash payments greater than $50,000. However, Cassidy notes that an operator will likely spend some time at the center because the federal employee has to check and double-check payments. The agency wants to work with companies in the cannabis space, regardless of the plant’s status with the federal government, to ensure it gets paid the taxes owed. Should lawmakers finally pass cannabis legislation, both cannabis companies and the IRS stand to benefit.

Cannabis banking reform will not only benefit the IRS but will also remove a major bottleneck faced by the entire marijuana industry, including sector players such as Hero Technologies Inc. (OTC: HENC).

NOTE TO INVESTORS: The latest news and updates relating to Hero Technologies Inc. (OTC: HENC) are available in the company’s newsroom at https://cnw.fm/HENC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — New Measure Will Give Scientists Access to Marijuana Dispensary Products

Last week, a group of federal legislators introduced the Medical Marijuana Research Act, which will eliminate barriers to carrying out research on cannabis. It will include permitting researchers to access marijuana from state-legal dispensaries. The measure was filed by Rep. Andy Harris, a prohibitionist, and Rep. Earl Blumenauer, a pro-legalization lawmaker. The bill will streamline the process for scientists to apply and gain approval to conduct research on marijuana.

In a recent interview, Blumenauer stated that federal legislations were still constraining researchers’ ability to study the various health benefits provided by marijuana, despite the fact that a majority of individuals in America are living in a state that has legalized some form of marijuana.

In late 2020, the House passed a similar version of the marijuana science measure. The Medical Marijuana Research Act, which was filed with support from half a dozen other cosponsors, will also make it easier for researchers to alter their research protocols without seeking federal approval. It would also mandate that the DEA license more cultivators and remove the limit on the number of organizations that can register to grow cannabis for research purposes.

In addition, it would also require that the Department of Health and Human Services present a report that offers an overview of the results of federal marijuana studies to Congress. Furthermore, it would remove additional layers of protocol review, minimize the number of costly security requirements and decrease approval wait times.

In his Congressional Record remarks, Blumenauer stated that the marijuana laws in the United States were broken, including the laws which govern research on marijuana. He explained that since marijuana was still classified as a Schedule I substance, scientists have to comply with strenuous requirements and jump through hoops just to conduct basic research on cannabis’ medical potential.

A Schedule I substance under the Controlled Substances Act refers to drugs that aren’t approved for medical use because they have a high potential for abuse. Blumenauer asserted that expanded research would ensure that Americans had adequate access to transformative treatments and medicines. For about 50 years now, scientists have only been able to conduct research on cannabis grown at the sole federally approved facility located at the University of Mississippi.

In related news, the DEA proposed a significant increase in the amount of cannabis and psychedelics such as mescaline, MDMA, LSD and psilocybin that it wants to be produced in the country for research purposes in 2022. This is after it announced in May that it would soon begin licensing new marijuana growers.

It would be interesting to see how the era of scientists legally using dispensary-sourced cannabis products will pan out when those researchers make use of state-of-the-art dose-measuring devices such as those manufactured by RYAH Group Inc. (CSE: RYAH).

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CBDNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC), GlossWire Partner to Launch MIND Naturals and Awe (Ô) CBD Skincare Brands

Flora Growth Corp. (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, today announced that its Flora Beauty division has signed an agreement with GlossWire to feature its two skincare brands, MIND Naturals and Awe (Ô), on GlossWire’s digital beauty marketplace. The campaign launch with GlossWire, an innovative global marketplace featuring a highly curated mix of emerging and established brands, is expected to begin Nov. 10, 2021. “We are very excited to see an innovative technology platform like GlossWire seek our brands for their marketplace. This unique intersection of tech and beauty allows for discovery, storytelling and a deeper understanding of the customer,” said Luis Merchan, president and CEO of Flora Growth. “Partnering with a platform like GlossWire not only increases market awareness for MIND Naturals and Awe (Ô), but also allows us to further differentiate our brands by tailoring future products and offerings to our customers’ needs.”

To view the full press release, visit https://cnw.fm/J4TAQ

About Flora Growth Corp.

Flora is a cannabis company that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive. Visit www.FloraGrowth.ca or follow @floragrowthcorp on social for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

420 with CNW — Why CBD Is Viable Treatment for Skin Inflammation

Cannabidiol, or CBD, is one of the two common compounds found in marijuana, the other being THC. Unlike THC, which is a psychoactive compound, CBD is a nonpsychoactive compound. These compounds can be derived directly from the hemp plant or manufactured in a lab. Research has shown that CBD holds the potential for the treatment of various conditions, including post-traumatic stress disorder, depression and anxiety.

It also possesses anti-inflammatory and antibacterial properties, which can help control various skin issues that commonly affect skin. Its anti-inflammatory properties in particular can be used to treat different skin illnesses. Some consumers prefer using CBD skincare products instead of other skincare and beauty products in the market. Below are some of the benefits one can derive from using CBD for skin inflammation.

CBD can be used to manage acne

Acne is a common inflammatory condition that affects individuals across the globe. It can cause redness and puffiness in an individual’s face, among other things.

CBD can help control acne by managing the redness, puffiness and inflammation associated with this common skin condition. This means that it’s possible for individuals affected with acne to keep their skin healthy and clear using CBD.

CBD can manage inflammation caused by aging

Inflammation is one of the signs of aging that can be seen in individuals. Inflammation is mainly brought about by the accumulation of free radicals on the skin in a process known as oxidative stress.

CBD’s excellent antioxidant properties can be used to control the inflammation caused by oxidative stress, which will in turn help reduce the visible signs of aging on an individual’s skin. This means that CBD skincare products can be used to keep an individual’s skin healthy, young and glowing.

In addition, CBD can also help control various skin diseases such as acne and psoriasis, which means that CBD skincare products can help manage different skin diseases naturally.

CBD can reduce inflammation caused by psoriasis

Psoriasis is a skin disease that causes itchy, scaly and red patches on the scalp, trunk, elbows and knees of an individual. This disease causes difficulties in individuals who suffer from this condition. CBD may help control this skin disease by reducing the inflammation associated with psoriasis and related disorders. CBD has also demonstrated its potential in reducing other symptoms associated with psoriasis, such as pain, swelling and scaly patches.

Companies such as Flora Growth Corp. (NASDAQ: FLGC) are leveraging the anti-inflammatory attributes of CBD by including this cannabinoid in the formulation of their beauty products, and from the way these products are growing in popularity, consumers seem to be receiving value for their money.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Follow These Expert Suggestions When Sourcing CBD Oil

CBD was legalized in 2018 when the farm bill allowed the cultivation and sale of industrial hemp and its derivatives. Soon after, the hemp extract was enjoying growing popularity as people flocked to buy products such as CBD oil and gummies, partly due to its purported medical benefits. However, the industry is barely regulated by the federal government, and this has allowed some dishonest sellers to slip in and sell subpar and even contaminated CBD oil. The next time you want to buy CBD oil, keep the following tips in mind to ensure you do not end up with a subpar product that could compromise your health.

Request a Certificate of Analysis (“COA”). A COA is a document that outlines the CBD oil’s ingredients and provides the results of extensive tests for any contaminants. A COA is proof of transparency and shows that a company has confidence in the quality and safety of its products. Any CBD company that refuses to provide a Certificate of Analysis should have your alarm bells ringing: either they haven’t had their products tested to see if they meet safety standards or they have received negative feedback but would rather sell their products as is.

Once you get your hands on a product’s COA, make sure it has these three panels:

A cannabinoid analysis that indicates the concentration and weight of the cannabinoids in the CBD oil. Trace levels of THC can build up in your system and lead to a failed drug test
A heavy metal analysis panel indicating the levels of heavy metals such as mercury and lead. Extended exposure to these metals can severely disrupt your health. Any CBD oil product that has more than 0.001 mg/mL of cadmium, 0.0001 mg/mL of mercury, or 0.003 mg/mL of lead is a big no.
A pesticides analysis panel. Hemp will absorb any chemical agents that are introduced as it develops including herbicides, pesticides and fertilizers. Continued exposure to these chemicals can disrupt your hormones, weaken your immunity and even cause liver toxicity.

Check that the testing was done by a third-party laboratory as it is proof of accurate and unbiased testing. A dishonest company is likely to fudge its internal tests if those tests produce unfavorable results.

Furthermore, you should also do a quick search on the lab to make sure it is qualified and trustworthy. If you have allergies, have a look at the ingredients as well and ensure the CBD oil is organic. Full-spectrum CBD oil will have every other cannabinoid except THC, and most CBD oils use either MCT oil, almond oil, sunflower oil, olive oil or vegetable oil as a carrier oil. Some companies also offer vegan CBD oil and gluten-free CBD oil, which will most likely be indicated in the list of ingredients or labels.

Finally, ask plenty of questions. Look at product reviews and talk to people who have used specific CBD products. Make sure you speak to your doctor too, especially if you are pregnant or on other medication.

Companies that make medicinal CBD products, such as Simply Sonoma Inc., appear to hold themselves to an even higher standard. Users would be well advised to do their due diligence in order to identify reputable companies that are committed to manufacturing high-quality products.

NOTE TO INVESTORS: The latest news and updates relating to Simply Sonoma Inc. are available in the company’s newsroom at https://cnw.fm/Sonoma

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) Eyes Opportunity in Largely Untapped Market

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), a diversified health and wellness beverage and natural products company, recently announced a series of new corporate developments designed to further broaden its commercial prospects. Among these, BevCanna recently entered into a sales service agreement with Velvet Management Inc., Canada’s leading cannabis sales agency. In addition, the company signed multiple product purchase agreements with the British Columbia Liquor Distribution Branch (‘BCLDB’), a testament to BevCanna’s rapidly expanding distribution network across Canada. This comes on the heels of two similar agreements with Alberta Gaming and Liquor Commission (‘AGLC’) and Ontario Cannabis Store (“OCS”). “Functional drinks and drinks based on plant derivatives — including those containing cannabis- or hemp-derived ingredients like cannabidiol (‘CBD’) or tetrahydrocannabinol (‘THC’) — have rapidly established themselves as one of the fastest-growing verticals within the North American beverage industry,” reads a recent article discussing the company’s positioning. The piece also mentions a recent study forecasting the global cannabis drinks sector to triple in value to $5.8 billion by 2024. “While a number of large global brands, including AB InBev and Molson Coors have recently announced plans to produce CBD-containing products, there is no doubt that the cannabis drinks market remains largely untapped.”

To view the full article, visit https://cnw.fm/6FGZN

About BevCanna Enterprises Inc.

BevCanna Enterprises is a diversified health and wellness beverage and natural products company. BevCanna develops and manufactures a range of alkaline, plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients. With decades of experience creating, manufacturing and distributing iconic brands that resonate with consumers on a global scale, the team demonstrates an expertise unmatched in the nutraceutical and cannabis-infused beverage categories. Based in British Columbia, Canada, BevCanna owns a pristine alkaline spring water aquifer and a world–class 40,000–square–foot, HACCP-certified manufacturing facility, with a bottling capacity of up to 210M bottles annually. BevCanna’s extensive distribution network includes more than 3,000 points of retail distribution through its market-leading TRACE brand, its Pure Therapy natural health and wellness e-commerce platform, its fully licensed Canadian cannabis manufacturing and distribution network, and a partnership with top U.S. cannabis beverage company Keef Brands. For more information about the company, visit www.BevCanna.com.

NOTE TO INVESTORS: The latest news and updates relating to BVNNF are available in the company’s newsroom at http://cnw.fm/BVNNF

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – CWCBExpo to Cover Essential Topics in Upcoming NYC Event

Cannabis World Congress & Business Exposition (“CWCBExpo”), the premier East Coast trade show and conference dedicated to the legalized cannabis industry, is ramping up for its return to New York City; the expo is scheduled for Nov. 4–6, 2021, at New York City’s Javits Convention Center. The event is designed to be a leading business forum for dispensary owners, growers, suppliers, investors, medical professionals, government regulators and entrepreneurs working in the space to achieve commercial success and identify new areas of growth. The agenda for CWCBExpo New York is committed to delivering in-depth educational information and material that discusses all facets of the cannabis, CBD and hemp-based sectors. Keynote addresses, expert panels and Inside the Industry: A Thought Leadership Series cover timely, relevant topics, including industry updates, opportunities and tips for success. The conference also provides valuable networking opportunities and an exhibit center that spotlights some of the industry’s latest innovations, products and services. The CWCBExpo seeks to offer attendees insights on how to leverage the full potential of the cannabis market.

To participate in the event, visit https://cnw.fm/fO5Jk

To view the full press release, visit https://cnw.fm/QH2hV

About the Cannabis World Congress & Business Exposition

CWCBExpo is a business-to-business trade show event for the legalized cannabis industry. It is held in the largest media, financial and business markets. It is the leading forum for dispensary owners, growers, suppliers, investors, medical professionals, government regulators, legal counsel and entrepreneurs looking to achieve business success and identify new areas of growth in this dynamic and fast-growing industry. For more information about the company, visit www.CWCBExpo.com.

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Cannabis Strategic Ventures Inc. (NUGS) Enters MOU to Acquire Top-Tier Indoor Cannabis Cultivation Facility

Cannabis Strategic Ventures (OTCQB: NUGS), an emerging leader in the U.S. cannabis marketplace, today announced its entry into a memorandum of understanding (“MOU”) between Cannabis Strategic Ventures and Devine Solutions Inc., a California corporation. The MOU relates to the proposed acquisition by NUGS of an indoor cannabis cultivation facility in Sacramento, California. Under the terms of the MOU, the company intends to purchase 10% of the facility at a valuation of $15 million for the entire facility, with an option to purchase an additional 41% of the facility (which would comprise a controlling 51% stake) at this same valuation. “This deal represents the potential to sharply increase our premium cannabis production capacity and materially augment our status as an emerging leader in the vertically integrated California cannabis marketplace,” said Simon Yu, CEO of NUGS. “We have already amassed years of experience refining our cultivation methods and strains in an outdoor framework with our NUGS Farm North site. Adding a top-tier indoor cultivation operation stands to help us further build upon that success and drive more volume in the premium flower market, which has powerful implications given our recent expansion into the dispensary marketplace with our MDRN Tree downtown LA dispensary location. The combination grants NUGS expanding operations at both ends of the farm-to-sale model.”

To view the full press release, visit https://cnw.fm/9U1m7

About Cannabis Strategic Ventures Inc.

Cannabis Strategic Ventures is one of the largest publicly traded marijuana cultivators in the United States. The company is Los Angeles-based and incubates, develops and partners with category leaders within the cannabis and ancillary sectors. The firm’s NUGS brand experience provides operational and financial strategic partnerships and a range of essential services to emerging and existing Cannabis consumer brands. For more information, visit www.CannabisStrategic.com.

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.